13,039 results match your criteria Lymphoma Follicular

FDA Evaluating Possible Serious Risks From Umbralisib.

Am J Nurs 2022 Jun;122(6):23

Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch:

Initial clinical trial data for umbralisib (Ukoniq), a drug currently approved to treat relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma, indicate that umbralisib may increase the risk of death or serious adverse effects when given with a specific monoclonal antibody to treat chronic lymphocytic leukemia.Patients receiving umbralisib to treat lymphomas should be evaluated closely for adverse effects. Nurses and other health care providers should report any of these adverse effects to the Food and Drug Administration's MedWatch program. Read More

View Article and Full-Text PDF

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.

Front Pharmacol 2022 9;13:875372. Epub 2022 May 9.

Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, China.

The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets have been studied, showing dual PI3K/mTOR inhibition compared with single targeting small molecule inhibitors. Read More

View Article and Full-Text PDF

Exome sequencing identifies PD-L2 as a potential predisposition gene for lymphoma.

Hematol Oncol 2022 May 25. Epub 2022 May 25.

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA.

To investigate germline predisposition in lymphoma, we performed whole-exome sequencing and discovered a novel variant (c.817-1G>T) in programmed cell death 1 ligand 2 (PD-L2) in a family with early-onset lymphomas and other cancers. The variant was present in the proband with follicular lymphoma and his son with Hodgkin's lymphoma. Read More

View Article and Full-Text PDF

PNMZL and PTFL: morphological variants with a common molecular profile - a unifying hypothesis.

Blood Adv 2022 May 24. Epub 2022 May 24.

University of Tuebingen, Tuebingen, Germany.

Pediatric nodal marginal zone lymphoma (PNMZL) is an uncommon B-cell neoplasm affecting mainly male children and young adults. This indolent lymphoma has distinct characteristics that differ from conventional nodal marginal zone lymphoma (NMZL). Clinically, it shows overlapping features with pediatric-type follicular lymphoma (PTFL). Read More

View Article and Full-Text PDF

Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report.

Curr Med Res Opin 2022 May 24:1-5. Epub 2022 May 24.

Operative Unit of Infectious Diseases, "V. Fazzi" Hospital, Lecce, Italy.

Coronavirus Disease 2019 (COVID-19) is affecting millions of people globally. Several neutralizing monoclonal antibodies have been developed to limit the progression and complications of the disease. These treatments provide immediate and passive immunity. Read More

View Article and Full-Text PDF

Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses.

Am J Hematol 2022 May 24. Epub 2022 May 24.

Haematology Department, Concord Repatriation General Hospital, Sydney, NSW, Australia.

Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk of severe COVID-19. Patients and healthy controls (HC; N=13) received 2 doses of BNT162b2: Follicular Lymphoma (FL; N=35) who were treatment naïve (TN; N=11) or received immunochemotherapy (ICT; N=23) and Waldenström's Macroglobulinemia (WM; N=37) including TN (N=9), ICT (N=14), or treated with Bruton's Tyrosine Kinase inhibitors (BTKi; N=12). Anti-spike IgG was determined by a high-sensitivity flow-cytometric assay, in addition to live-virus neutralization. Read More

View Article and Full-Text PDF

Neurolymphomatosis in follicular lymphoma: an autopsy case report.

Neuropathology 2022 May 23. Epub 2022 May 23.

Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.

Neurolymphomatosis is a neurological manifestation of lymphoma that involves the cranial or spinal peripheral nerves, nerve roots, and plexus with direct invasion of neoplastic cells. Neurolymphomatosis is rare among patients with low-grade lymphoma. We report an autopsied case of neurolymphomatosis that arose from follicular lymphoma. Read More

View Article and Full-Text PDF

Ocular adnexal lymphoma: A single-institution retrospective study.

Saudi J Ophthalmol 2021 Jul-Sep;35(3):230-238. Epub 2022 Apr 18.

Department of Pathology, Wills Eye Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA.

Purpose: To characterize demographic, clinical, and histopathologic features of ocular adnexal lymphoma (OAL) at a single institution.

Methods: Retrospective review of all patients with pathologic diagnosis of OAL between 2015 and 2020.

Results: There were 133 patients with OAL, with a median age of 65 years (range 23-97) and a slight female predominance (male: female = 1:1. Read More

View Article and Full-Text PDF

Unusual presentation of extra-nodal double-hit follicular lymphoma: a case report.

BMC Gastroenterol 2022 May 20;22(1):254. Epub 2022 May 20.

Institute of Pathology and Neuropathology, Tübingen University Hospital and Comprehensive Cancer Center Tübingen-Stuttgart, Tübingen, Italy.

Background: To the best of our knowledge, this case represents the first report of an extranodal double-hit follicular lymphoma (DH-FL) as an intestinal polypoid lesion.

Case Presentation: A 72-year-old woman presents with constipation. Colonoscopy reveals a sessile polypoid lesion of the colon bearing morphological, immunohistochemical and molecular hallmarks of DH-FL. Read More

View Article and Full-Text PDF

Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-14

BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.

Diffuse large B-cell lymphoma and follicular lymphoma are the most commonly encountered non-Hodgkin lymphomas in clinical practice. Both are biologically heterogeneous, with management strategies that are becoming increasingly complex. Diffuse large B-cell lymphoma typically exhibits aggressive behavior but can be cured in the majority of cases with immunochemotherapy. Read More

View Article and Full-Text PDF

Impact of PET-CT status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplant.

Haematologica 2022 May 19. Epub 2022 May 19.

Department of Haematology, University College London Hospitals 235 Euston Road, London.

The optimum management approach for patients with relapsed or refractory (R/R) follicular lymphoma (FL) remains uncertain. Autologous stem cell transplantation (autoSCT) is considered a standard option in suitable, younger patients with relapsed FL. AutoSCT is associated with very durable remissions in a minority but also significant, wellestablished toxicities. Read More

View Article and Full-Text PDF

Contained abdominal aortic rupture secondary to follicular lymphoma invasion.

J Vasc Surg Cases Innov Tech 2022 Jun 11;8(2):271-274. Epub 2022 Apr 11.

Department of Vascular Surgery, Maimonides Medical Center, Brooklyn, NY.

An 87-year-old woman with grade IIIb follicular lymphoma treated with rituximab had presented with nausea, emesis, and chest pain of 1 day duration. She was found to have a contained abdominal aortic rupture secondary to follicular lymphoma invasion. She safely and successfully underwent emergent endovascular aortic repair. Read More

View Article and Full-Text PDF

The role of surveillance computed tomography in patients with follicular lymphoma.

Ther Adv Hematol 2022 14;13:20406207221095963. Epub 2022 May 14.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Introduction: Surveillance computed tomography (CT) is performed during the follow-up of patients with lymphoma who have completed initial therapy. However, studies on the clinical benefit of surveillance CT for patients with incurable subtypes, such as follicular lymphoma (FL), are limited. This study aimed to evaluate the value of surveillance CT for patients with FL after achieving the first complete response (CR) or CR unconfirmed in the rituximab era. Read More

View Article and Full-Text PDF

NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome.

Sci Rep 2022 May 18;12(1):8294. Epub 2022 May 18.

Department of Pathology and Laboratory Medicine, Foothills Medical Centre, Cumming School of Medicine, University of Calgary, McCaig Tower, Room MT7523, 1403 29 St NW, Calgary, AB, T2N 2T9, Canada.

Follicular lymphoma (FL) is a cancer of B-cells, representing the second most common type of non-Hodgkin lymphoma and typically diagnosed at advanced stage in older adults. In contrast to the wide range of available molecular genetic data, limited data relating the metabolomic features of follicular lymphoma are known. Metabolomics is a promising analytical approach employing metabolites (molecules < 1 kDa in size) as potential biomarkers in cancer research. Read More

View Article and Full-Text PDF

Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.

Int J Hematol 2022 May 18. Epub 2022 May 18.

Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.

Progression-free survival in patients with untreated follicular lymphoma (FL) has significantly improved with obinutuzumab plus chemotherapy followed by obinutuzumab maintenance, compared with rituximab plus chemotherapy. However, the survival outcome and adverse event profile in Japanese FL patients treated with obinutuzumab plus bendamustine (GB) therapy are not well investigated. Recently, we encountered some cases of grade 3-4 thrombocytopenia during GB therapy in patients with FL. Read More

View Article and Full-Text PDF

Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.

J Cell Physiol 2022 May 16. Epub 2022 May 16.

Animal Genetics, Breeding and Reproduction Laboratory, College of Animal Science, Shanxi Agricultural University, Taigu, Shanxi, China.

Protein neddylation inactivation is a novel topic in cancer research. However, there are few studies on the mechanism of neddylation underlying the development of sheep follicular granulosa cells (GCs). In this study, the development of follicular GCs in sheep was inactivated by MLN4924, a neddylation-specific inhibitor, which significantly attenuated the proliferation and cell index of sheep follicular GCs. Read More

View Article and Full-Text PDF

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes.

Oncotarget 2022 11;13:677-683. Epub 2022 May 11.

Lymphoma Research Foundation, New York, NY 10005, USA.

Purpose: In the tazemetostat E7438-G000-101 trial of relapsed/refractory (R/R) follicular lymphoma (FL), apparent superior efficacy was suggested for mutant-type (MT) versus wild-type (WT) status. However, clinical disparities might have contributed to this conclusion. This study aimed to estimate outcomes after minimizing differences in baseline characteristics. Read More

View Article and Full-Text PDF

Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma.

Cancers (Basel) 2022 Apr 26;14(9). Epub 2022 Apr 26.

Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain.

Follicular lymphomas (FL) are neoplasms that resemble normal germinal center (GC) B-cells. Normal GC and neoplastic follicles contain non-neoplastic cells such as T-cells, follicular dendritic cells, cancer associated fibroblasts, and macrophages, which define the tumor microenvironment (TME), which itself is an essential factor in tumor cell survival. The main characteristics of the TME in FL are an increased number of follicular regulatory T-cells (T) and follicular helper T-cells (T), M2-polarization of macrophages, and the development of a nodular network by stromal cells that creates a suitable niche for tumor growth. Read More

View Article and Full-Text PDF

CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma.

Cancers (Basel) 2022 Apr 26;14(9). Epub 2022 Apr 26.

Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Barcelona, Casanova 172, 08036 Barcelona, Spain.

CD229 (Ly9) homophilic receptor, which belongs to the SLAM family of cell-surface molecules, is predominantly expressed on B and T cells. It acts as a signaling molecule, regulating lymphocyte homoeostasis and activation. Studies of CD229 function indicate that this receptor functions as a regulator of the development of marginal-zone B cells and other innate-like T and B lymphocytes. Read More

View Article and Full-Text PDF

Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.

Eur J Immunol 2022 May 12. Epub 2022 May 12.

Tumor Immunology Unit, Department of Sciences for Health Promotion and Mother-Child Care "G. D'Alessandro", University of Palermo, Palermo, Italy.

The germinal center (GC) reaction results in the selection of B-cells acquiring effector Ig secreting ability by progressing towards plasmablastic differentiation. This transition is associated with exclusion from the GC microenvironment. The aberrant expansion of plasmablastic elements within the GC fringes configures an atypical condition, the biological characteristics of which have not been defined yet. Read More

View Article and Full-Text PDF

Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8 T-cells despite immune checkpoint signaling.

Blood Res 2022 May 13. Epub 2022 May 13.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Background: B-cell non-Hodgkin lymphomas (NHL) are hematologic malignancies that arise in the lymph node. Despite this, the malignant cells are not cleared by the immune cells present. The failure of anti-tumor immunity may be due to immune checkpoints such as the PD-1/PDL-1 axis, which can cause T-cell exhaustion. Read More

View Article and Full-Text PDF

Loss of RARRES1 function Promotes Follicular Lymphomagenesis and Inhibits B cell Differentiation in Mice.

Int J Biol Sci 2022 28;18(7):2670-2682. Epub 2022 Mar 28.

Georgetown-Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.

Retinoic acid receptor responder 1 (RARRES1) is among the most commonly methylated loci in multiple cancers. RARRES1 regulates mitochondrial and fatty acid metabolism, stem cell differentiation, and survival of immortalized cell lines . Here, we created constitutive knockout ( ) mouse models to study RARRES1 function . Read More

View Article and Full-Text PDF

Targeting Apoptosis in ALL.

Curr Hematol Malig Rep 2022 04 11;17(2):53-60. Epub 2022 May 11.

Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC, USA.

Purpose Of Review: While the treatment of acute lymphoblastic leukemia (ALL) has improved significantly over the last 30 years, the majority of adult patients will have their disease relapse. The BCL-2 gene was initially discovered from follicular lymphoma research; however, the BH3 family of proteins has is emerging to be crucial in patients with ALL due to their reliance on the balance of these pro-apoptotic and anti-apoptotic proteins in the BH3 family. We discuss apoptosis in ALL, the reliance mechanisms, drug development in this space, and areas for future research. Read More

View Article and Full-Text PDF

The genomic and transcriptional landscape of primary central nervous system lymphoma.

Nat Commun 2022 May 10;13(1):2558. Epub 2022 May 10.

Department for Neurosurgery, Vivantes Klinikum Neukölln, Berlin, Germany.

Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell lymphomas (DLBCLs) confined to the central nervous system (CNS). Molecular drivers of PCNSL have not been fully elucidated. Here, we profile and compare the whole-genome and transcriptome landscape of 51 CNS lymphomas (CNSL) to 39 follicular lymphoma and 36 DLBCL cases outside the CNS. Read More

View Article and Full-Text PDF

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.

Blood Adv 2022 May 10. Epub 2022 May 10.

University of Munich, Munich, Germany.

This phase I study evaluated safety, tolerability and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two dose levels of venetoclax were evaluated with an expansion cohort at the recommended phase 2 dose. Twenty-five patients were enrolled. Read More

View Article and Full-Text PDF

Utility of F-fluorodeoxyglucose PET-CT scan in detecting bone marrow involvement in lymphoma.

Indian J Med Res 2021 May;154(5):691-698

Department of Hematology, Nilratan Sircar Medical College, Kolkata, West Bengal, India.

Background & Objectives: Evaluation of bone marrow infiltration in lymphoma is usually done by bone marrow biopsy (BMB). This study analyzed the utility of F-fluorodeoxyglucose positron emission tomography/computerized tomography (F-FDG PET/CT) to detect bone marrow involvement (BMI) compared to BMB.

Methods: Treatment-naïve lymphoma patients underwent both F-FDG PET/CT scan and BMB before treatment initiation. Read More

View Article and Full-Text PDF

Granulomatous splenic mass with necrosis revealing an EBV-positive inflammatory follicular dendritic cell sarcoma.

J Surg Case Rep 2022 May 5;2022(5):rjac034. Epub 2022 May 5.

Department of Pathology, Ambroise-Paré Hospital, AP-HP, Boulogne-Billancourt 92100, France.

Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma is a variant of follicular dendritic cell neoplasm most often arising in the liver or spleen. Two histological patterns can be identified in this variant, namely a granulomatous and an eosinophil-rich one. We present the case of a 69-year-old woman with a splenic mass. Read More

View Article and Full-Text PDF

Gastric Plexiform Fibromyxoma Resected Using Nonexposed Endoscopic Wall-Inversion Surgery: A Case Report.

Case Rep Gastroenterol 2022 Jan-Apr;16(1):159-164. Epub 2022 Mar 28.

Department of Gastroenterology, Aichi Medical University School of Medicine, Nagakute, Japan.

Gastric plexiform fibromyxoma is extremely rare. In our case, upper gastrointestinal endoscopy of a 41-year-old woman patient revealed a 1-cm submucosal tumor (SMT) in the greater curvature of the lower body of the stomach. On contrast-enhanced computed tomography, the tumor was hypervascular in the arterial phase with continuous enhancement in the post-venous phase. Read More

View Article and Full-Text PDF

Non-Hodgkin's lymphoma Breast in a lactating mother : Case Report.

Nepal J Epidemiol 2022 Mar 31;12(1):1163-1170. Epub 2022 Mar 31.

Department of General Surgery, All India Institute of Medical Sciences, New Delhi, India.

Non-Hodgkin's lymphoma of breast is a rare condition. NHL breast constitute about 0.5% of all malignancies of breast. Read More

View Article and Full-Text PDF